EHL
10.3.2017 11:02:27 CET | Business Wire | Press release
Ecole hôtelière de Lausanne (EHL) has been awarded a survey-based score of 100% for graduate reputation amongst employers in the 2017 QS World University ranking. In the ranking of Hospitality & Leisure Management Universities, EHL is ranked 2 nd worldwide, with the University of Nevada taking first place. The rankings are based on academic reputation, reputation with employers and research impact.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170310005234/en/
The most recent rankings confirm Switzerland’s central role in shaping the hospitality industry, with 3 hospitality management schools present in the top 10, led by EHL with its consistently exceptional performance in the field.
EHL Group CEO Michel Rochat reacted to the news by saying that “being the highest ranked hospitality university, outside the U.S., is an honor and a welcomed recognition of our relentless commitment to paving the way for Swiss hospitality”. “I also wish to congratulate our friends in neighboring Swiss hospitality management schools who performed very well in this latest ranking. Healthy competition is a key driver behind our success and the ability of the hospitality industry –as a whole- to remain innovative and relevant”, he added.
EHL puts a great focus on continually developing its academic programs, with new graduate and online programs, and on strengthening industry ties to offer the best career opportunities for students, which is evidenced by an employment rate of more than 95% for young graduates. The noticeable EHL score in the latest QS global ranking is yet another testament of the school’s ability to grow and diversify, while remaining true to its identity and standards of excellence.
About Ecole hôtelière de Lausanne (EHL)
Ecole hôtelière de Lausanne (EHL) is an ambassador for traditional Swiss hospitality and has been a pioneer in hospitality education since 1893. It has created and inspired a unique professional community of 25,000 hospitality managers, united by the values and the legacy of EHL.
EHL offers five academic programs; a Bachelor, a Master of Science, an MBA, an Executive MBA and a Master Class. The academic portfolio is developed to evolve and adapt to the needs of both the industry and the students, and offers a wide range of possibilities that make an EHL education flexible and accessible to young talents from all around the world.
EHL is regularly recognized as the best hotel management school in the world, offering university studies to 2,685 enthusiastic and talented students from 106 different nationalities. EHL is a member of EHL Holding SA, a Group dedicated to hospitality management education.
For more information, please visit our website or follow us on twitter @EHLnews
View source version on businesswire.com: http://www.businesswire.com/news/home/20170310005234/en/
Contact:
Ecole hôtelière de Lausanne
Sherif Mamdouh, +41 21 785 10 53
Senior
Communications Officer
communication@ehl.ch
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom